Selective blockade of prostaglandin E2 receptors EP2 and EP4 signaling inhibits proliferation of human endometriotic epithelial cells and stromal cells through distinct cell cycle arrest

Fertility and Sterility

Volumn 93, Issue 8, 2010, Pages 2498-2506

  Lee, JeHoon ^a   Banu, Sakhila K ^a   Rodriguez, Royce ^a   Starzinski Powitz, Anna ^b   Arosh, Joe A ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

cell cycle; cell proliferation; endometriosis; EP receptors; humans; immortalized endometriotic cells; PGE2 signaling

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLINE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E4; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIOSIS; ENDOMETRIUM CELL; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REGULATORY MECHANISM; UPREGULATION;

BIPHENYL COMPOUNDS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; PROSTAGLANDIN ANTAGONISTS; RECEPTORS, PROSTAGLANDIN E; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STROMAL CELLS; XANTHONES;

EID: 77952111663     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.01.038     Document Type: Article

References (57)

1. Bulun S.E. Endometriosis. N Engl J Med 360 (2009) 268-279
2. Giudice L.C., and Kao L.C. Endometriosis. Lancet 364 (2004) 1789-1799
3. Olive D.L. Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med 359 (2008) 1136-1142
4. Sampson J. Peritoneal endometritis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 14 (1927) 442-469
5. Osteen K.G., Bruner-Tran K.L., and Eisenberg E. Endometrial biology and the etiology of endometriosis. Fertil Steril 84 (2005) 33-34 [discussion: 8-9]
6. Guo S.W., and Olive D.L. Two unsuccessful clinical trials on endometriosis and a few lessons learned. Gynecol Obstet Invest 64 (2007) 24-35
7. Wu M.H., Shoji Y., Chuang P.C., and Tsai S.J. Endometriosis: disease pathophysiology and the role of prostaglandins. Expert Rev Mol Med 9 (2007) 1-20
8. Laschke M.W., Elitzsch A., Scheuer C., Vollmar B., and Menger M.D. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 87 (2007) 163-171
9. Banu S.K., Lee J., Speights V.O., Starzinski-Powitz A., and Arosh J.A. Cyclooxygenase-2 regulates survival, migration and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 149 (2008) 1180-1189
10. Matsuzaki S., Canis M., Darcha C., Dallel R., Okamura K., and Mage G. Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 82 (2004) 1609-1615
11. Ozawa Y., Murakami T., Tamura M., Terada Y., Yaegashi N., and Okamura K. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril 86 Suppl 4 (2006) 1146-1151
12. Wu M.H., Wang C.A., Lin C.C., Chen L.C., Chang W.C., and Tsai S.J. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 90 (2005) 286-295
13. Chishima F., Hayakawa S., Sugita K., Kinukawa N., Aleemuzzaman S., Nemoto N., et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 48 (2002) 50-56
14. Ota H., Igarashi S., Sasaki M., and Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16 (2001) 561-566
15. Karck U., Reister F., Schafer W., Zahradnik H.P., and Breckwoldt M. PGE2 and PGF2 alpha release by human peritoneal macrophages in endometriosis. Prostaglandins 51 (1996) 49-60
16. Allen C., Hopewell S., and Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev (2005) CD004753
17. Smith W.L., and Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 68-69 (2002) 115-128
18. Becker C.M., Sampson D.A., Rupnick M.A., Rohan R.M., Efstathiou J.A., Short S.M., et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 84 Suppl 2 (2005) 1144-1155
19. Cobellis L., Razzi S., De Simone S., Sartini A., Fava A., Danero S., et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 116 (2004) 100-102
20. Kim Y.A., Kim M.R., Lee J.H., Kim J.Y., Hwang K.J., Kim H.S., et al. Gonadotropin-releasing hormone agonist reduces aromatase cytochrome P450 and cyclooxygenase-2 in ovarian endometrioma and eutopic endometrium of patients with endometriosis. Gynecol Obstet Invest 68 (2009) 73-81
21. Olivares C., Bilotas M., Buquet R., Borghi M., Sueldo C., Tesone M., et al. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 23 (2008) 2701-2708
22. Cha Y.I., and DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58 (2007) 239-252
23. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 (1999) 1193-1226
24. Wang D., and Dubois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
25. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 (2002) 289-293
26. Jabbour H.N., and Sales K.J. Prostaglandin receptor signalling and function in human endometrial pathology. Trends Endocrinol Metab 15 (2004) 398-404
27. Regan J.W. EP2 and EP4 prostanoid receptor signaling. Life Sci 74 (2003) 143-153
28. Banu S.K., Lee J., Speights Jr. V.O., Starzinski-Powitz A., and Arosh J.A. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkB and b-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol 23 (2009) 1291-1305
29. Baek J.Y., Hur W., Wang J.S., Bae S.H., and Yoon S.K. Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J Gastroenterol 13 (2007) 1175-1181
30. Cheng J., Imanishi H., Amuro Y., and Hada T. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 99 (2002) 755-761
31. Cheng J., Imanishi H., Liu W., Nakamura H., Morisaki T., Higashino K., et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 95 (2004) 666-673
32. Dvory-Sobol H., Cohen-Noyman E., Kazanov D., Figer A., Birkenfeld S., Madar-Shapiro L., et al. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42 (2006) 422-426
33. Kardosh A., Blumenthal M., Wang W.J., Chen T.C., and Schonthal A.H. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 3 (2004) 55-62
34. Lin H.P., Kulp S.K., Tseng P.H., Yang Y.T., Yang C.C., and Chen C.S. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3 (2004) 1671-1680
35. Shin Y.K., Park J.S., Kim H.S., Jun H.J., Kim G.E., Suh C.O., et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65 (2005) 9501-9509
36. Yazawa K., Tsuno N.H., Kitayama J., Kawai K., Okaji Y., Asakage M., et al. Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest. Int J Cancer 113 (2005) 541-548
37. Zhi H., Wang L., Zhang J., Zhou C., Ding F., Luo A., et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 27 (2006) 1214-1221
38. Trifan O.C., and Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7 (2003) 207-222
39. Cheong E., Ivory K., Doleman J., Parker M.L., Rhodes M., and Johnson I.T. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 25 (2004) 1945-1952
40. Zeitvogel A., Baumann R., and Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 159 (2001) 1839-1852
41. Banu S.K., Lee J., Starzinski-Powitz A., and Arosh J.A. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Sterl 90 (2008) 972-987
42. Banu S.K., Starzinski-Powitz A., Speights V.O., Burghardt R.C., and Arosh J.A. Induction of peritoneal endometriosis in nude mice using human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in human. Fertil Steril 91 (2009) 2199-2209
43. Coleman R.A., Smith W.L., and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46 (1994) 205-229
44. Woodward D.F., Pepperl D.J., Burkey T.H., and Regan J.W. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochem Pharmacol 50 (1995) 1731-1733
45. Crider J.Y., Griffin B.W., and Sharif N.A. Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukot Essent Fatty Acids 62 (2000) 21-26
46. Arosh J.A., Banu S.K., Chapdelaine P., Emond V., Kim J.J., MacLaren L.A., et al. Molecular cloning and characterization of bovine prostaglandin E2 receptors EP2 and EP4: expression and regulation in endometrium and myometrium during the estrous cycle and early pregnancy. Endocrinology 144 (2003) 3076-3091
47. Matsuzaki S., Canis M., Pouly J.L., Botchorishvili R., Dechelotte P.J., and Mage G. Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis. Fertil Steril 86 (2006) 548-553
48. Johnson D.G., and Walker C.L. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39 (1999) 295-312
49. Malumbres M., and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 30 (2005) 630-641
50. Sanchez I., and Dynlacht B.D. New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol 16 (2005) 311-321
51. Schwartz G.K., and Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23 (2005) 9408-9421
52. Blundell R.A. The biology of p21. Am J Biochem Biotechnol 2 (2006) 33-40
53. Enge M., Bao W., Hedstrom E., Jackson S.P., Moumen A., and Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15 (2009) 171-183
54. Attar E., Tokunaga H., Imir G., Yilmaz M.B., Redwine D., Putman M., et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab 94 (2009) 623-631
55. Maia Jr. H., Maltez A., Studard E., Zausner B., Athayde C., and Coutinho E. Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium. Gynecol Endocrinol 21 (2005) 57-61
56. Smith O.P., Jabbour H.N., and Critchley H.O. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 22 (2007) 1450-1456
57. Milne S.A., Perchick G.B., Boddy S.C., and Jabbour H.N. Expression, localization, and signaling of PGE(2) and EP2/EP4 receptors in human nonpregnant endometrium across the menstrual cycle. J Clin Endocrinol Metab 86 (2001) 4453-4459